The Exciting New Field of HER2-Low Breast Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Clinical Research

Background:

• Human epidermal growth factor receptor-2 (HER2) targeted therapies have historically been limited to HER2-positive breast cancer (BC).
• Recent research has identified HER2-low BC (HER2 IHC 1-2+, FISH negative) as a new target population.
• This classification expands the potential benefit of HER2-directed treatments to a larger group of BC patients.

Purpose of the Study:

• To review the evolution of HER2-targeted therapies in breast cancer.
• To evaluate the efficacy of first-generation anti-HER2 agents in HER2-low BC.
• To explore the potential of novel HER2-directed therapies, including antibody-drug conjugates, and combination strategies for HER2-low BC.

Main Methods:

• Narrative review of existing literature and clinical trial data.
• Analysis of evidence for first-generation anti-HER2 agents in HER2-low BC.
• Review of emerging data on antibody-drug conjugates and combination therapies.

Main Results:

• First-generation anti-HER2 agents like trastuzumab have shown limited clinical applicability in HER2-low BC.
• Newer antibody-drug conjugates demonstrate significant promise and growing success in HER2-low BC.
• Ongoing trials are investigating combinations of anti-HER2 agents with immunotherapy, endocrine therapy, and CDK4/6 inhibitors.

Conclusions:

• HER2-low BC represents a significant population that may benefit from targeted therapies.
• Novel antibody-drug conjugates and combination strategies are crucial for improving outcomes in HER2-low BC.
• Further research aims to extend survival benefits to a broader spectrum of breast cancer patients through HER2-directed treatments.